Study guide

11.3 Generic Substitution & Product Selection

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

11.3 Generic Substitution & Product Selection

Key Takeaways Explain This Topic AI

Illinois drug product selection is authorized under 225 ILCS 85 §25 and defined with 410 ILCS 620/3.14 of the Illinois Food, Drug and Cosmetic Act.

If the prescriber does not prohibit selection, a pharmacist may dispense a different brand or nonbrand product of the same generic name with a lower unit price, using FDA therapeutically equivalent generics.

FDA Orange Book A-rated (therapeutically equivalent) products are the standard interchange framework; B-rated products are not treated as freely interchangeable equivalents.

Prescriber “may not substitute” / DAW / brand medically necessary instructions block generic selection; patients may also request the brand when substitution is otherwise allowed.

When substitution occurs, record the manufacturer (or other required identification) of the product dispensed; biosimilar interchange follows FDA interchangeable designations rather than inventing Illinois-only bans.

Last updated: August 2026

11.3 Generic Substitution & Product Selection

Quick Answer: Under 225 ILCS 85 §25 (with 410 ILCS 620/3.14 of the Illinois Food, Drug and Cosmetic Act), if the prescriber does not prohibit drug product selection , a pharmacist may dispense a different brand or nonbrand product of the same generic name that has a unit price less than the product specified—using generics the FDA has determined therapeutically equivalent ( Orange Book A-rated framework). Honor “may not substitute” / DAW / brand medically necessary orders. Record the manufacturer of the product dispensed. Patients may still prefer brand when selection is otherwise allowed.

NABP Area 4 (Pharmacy Operations) includes product selection . The Illinois MPJE tests whether you know when you may swap brands, what equivalence standard applies, and what documentation follows the swap.

  • Statutory Framework
  • Definitions and cross-references

The Pharmacy Practice Act defines drug product selection as the interchange for a prescribed pharmaceutical product in accordance with Section 25 of the Act and Section 3.14 of the Illinois Food, Drug and Cosmetic Act . That dual citation is intentional: pharmacy practice authority and food/drug misbranding-substitution rules work together. Dispensing a different drug without lawful selection authority is not “customer service”—it can be illegal substitution under 410 ILCS 620/3.14 concepts.

Core permission in 225 ILCS 85 §25

Key statutory conditions (teaching paraphrase of the Act’s structure):

  • The prescriber, when transmitting an oral or written prescription, does not prohibit drug product selection
  • The pharmacist may dispense a different brand name or nonbrand name product of the same generic name
  • The selected drug has a unit price less than the drug product specified on the prescription

A generic determined therapeutically equivalent by the FDA is available for substitution in Illinois under the Act and the Illinois Food, Drug and Cosmetic Act (with manufacturer notification pathways described in statute for public-health tracking)

Price condition matters on exams: Illinois links selection to a lower unit price than the product prescribed. Selecting a more expensive brand “just because” is not the statutory selection model.

Prescriber “may not substitute” mechanics

Section 25 requires prescription forms to include a signature line and the words “may not substitute.” The prescriber, in his or her own handwriting , places a mark beside “may not substitute” to block selection. Preprinted or rubber-stamped marks (and other deviations from the required format) are not permitted under the statutory format language. The prescriber signs in their own handwriting to authorize issuance.

Modern e-prescribing systems express the same clinical intent with structured DAW fields. Teach both paper-era statutory language and electronic practice reality:

  • Intent Typical expression Pharmacist action
  • Substitution allowed No prohibition; DAW 0 / blank May select lower-unit-price TE generic

Prescriber demands brand Handwritten “may not substitute,” “brand medically necessary,” DAW 1 Dispense brand as ordered

Patient demands brand Patient request when selection otherwise allowed Dispense brand; bill/DAW coding per payer rules

Generic not available Stockout of TE product Contact prescriber or use lawful alternative pathway—do not invent non-equivalent swaps

  • FDA Orange Book: Therapeutic Equivalence
  • A-rated vs B-rated (exam core)

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations ( Orange Book ) assigns therapeutic equivalence (TE) codes:

A-rated products are considered therapeutically equivalent to the reference listed drug (same active ingredient, dosage form, route, strength; bioequivalence demonstrated under FDA standards)

B-rated products are not considered therapeutically equivalent at that time

Illinois §25 points you to FDA therapeutic equivalence as the scientific gate for generic availability/substitution. Practical rule:

  • A-rated → eligible for ordinary generic interchange (subject to DAW/price/statutory conditions)
  • B-rated or unrated → do not treat as freely interchangeable “same generic” under the TE model
  • Pharmaceutical equivalence vs therapeutic equivalence
  • Concept Meaning
  • Pharmaceutical equivalents Same active ingredient, strength, dosage form, route
  • Bioequivalence Comparable rate/extent of absorption under study conditions

Therapeutic equivalents (A-rated) Pharmaceutical equivalents expected to have the same clinical effect and safety profile when administered as labeled

An ANDA generic must show bioequivalence to the reference listed drug—not superior efficacy, not a new mechanism of action.

Documentation When You Select

Section 25 requires that in every case where selection is made as permitted by the Illinois Food, Drug and Cosmetic Act, the pharmacist indicate on the pharmacy record of the filled prescription the name or other identification of the manufacturer of the drug dispensed. Why exams care:

  • Recalls are manufacturer-lot specific
  • Therapeutic response complaints need product identity
  • Diversion/quality investigations need a clear chain of what left the pharmacy

Labeling should also identify the product the patient actually received (established/proprietary name as required)—do not leave the patient thinking they received Brand X if you dispensed Manufacturer Y’s generic without transparent labeling.

Patient Rights and Counseling Touchpoints

Even when the prescriber allows selection:

The patient may prefer the brand and decline the generic (subject to cost/coverage consequences you should explain honestly)

When substitution occurs, good practice—and many payer/plan expectations—includes informing the patient that a generic equivalent is being dispensed

Appearance changes (shape/color) are a major adherence risk; warn patients that the same medicine may look different

Failure to communicate a swap is how “I thought they gave me the wrong drug” complaints become Board matters.

Narrow Therapeutic Index and Clinical Judgment

Some drugs have a narrow therapeutic index (NTI) (e.g., certain anticonvulsants, thyroid preparations, transplant immunosuppressants historically discussed in equivalence debates). Illinois does not require you to invent a free-standing absolute NTI ban list on the MPJE unless a stem supplies a specific legal prohibition. Correct professional approach:

  • Check Orange Book TE code
  • Honor any prescriber DAW / may not substitute

Use clinical judgment and, when needed, contact the prescriber before switching products mid-therapy on sensitive agents

Document the decision

Do not claim Illinois categorically forbids all generic interchange for every NTI drug if the statute/Orange Book still treat a product as A-rated and the prescriber did not prohibit selection—teach judgment + DAW + TE codes , not folklore bans.

Biosimilars (High Level—No Invented Illinois Bans)

Biosimilars are not classic small-molecule “generics.” They are highly similar biological products evaluated under a different FDA pathway. Key teaching points for Illinois MPJE without inventing unpublished state bans:

FDA Purple Book resources identify licensed biologics, biosimilars, and interchangeable biosimilars

Interchangeable designation is the federal concept closest to automatic pharmacy-level substitution of biologics (subject to state law)

Non-interchangeable biosimilars may still be used when the prescriber specifically orders that product—they are not “wrong,” but they are not automatic Orange-Book-style swaps

Follow any Illinois-specific biosimilar notification or documentation rules if a vignette states them; if not stated, do not invent absolute prohibitions—apply prescriber intent + FDA interchangeability + professional standards

Worked Examples

Example 1. Prescription: Lipitor 20 mg. No “may not substitute.” A-rated atorvastatin generic available at lower unit price. → Selection permitted; record manufacturer; label the product dispensed.

Example 2. Prescription: brand with handwritten mark at “may not substitute” / DAW 1 “brand medically necessary.” → Dispense brand; no generic swap.

Example 3. Patient requests brand Zoloft despite open substitution. → Patient choice; dispense brand if stocked/ordered; explain cost.

Example 4. Only B-rated product available for a reference brand. → Do not treat as TE automatic substitute; contact prescriber for authorization of a specific product.

  • Common Traps
  • Substituting when the prescriber prohibited selection
  • Ignoring the lower unit price condition in Illinois §25
  • Using B-rated products as if they were A-rated
  • Failing to record manufacturer after selection

Confusing therapeutic interchange across different molecules (e.g., switching lisinopril to losartan without a new order) with generic product selection of the same generic name

Inventing absolute Illinois NTI or biosimilar bans not given in the stem

Master §25 + 3.14 , Orange Book A ratings , DAW / may not substitute , manufacturer documentation , and patient preference . Section 11.4 covers emergency supply, OTC/BTC, and pseudoephedrine limits when ordinary prescriptions are not available.